CD19 and acute lymphoblastic leukemia: A significant drop in peripheral B cells was observed when we measured CD19+ B cells in the PB of humanized mice with B-ALL engraftment after treatment with blinatumomab, reminiscent of the B cell aplasia observed in patients (Figure 1E).